A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

April 18, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Thyroid Cancer
Interventions
DRUG

AL2846 Capsules

AL2846 Capsule is a multi - target tyrosine kinase inhibitor, which has significant inhibitory effects on c-Mesenchymal-epithelial transition factor (c - MET), stem cell factor receptor (c - KIT), VEGFR1 and Ret Proto-Oncogene (RET).

DRUG

AL2846 Placebo

AL2846 Placebo without drug substance.

Trial Locations (35)

21002

NOT_YET_RECRUITING

The Affiliated Hospital of XuZhou Medical University, Xuzhou

61012

NOT_YET_RECRUITING

CangZhou Center Hospital, Cangzhou

100021

NOT_YET_RECRUITING

cancer hospital Chinese academy of medical sciences, Beijing

110000

NOT_YET_RECRUITING

Liaoning Cancer Hospital, Shengyang

130000

NOT_YET_RECRUITING

China-Japan Union Hospital of Jilin University, Changchun

NOT_YET_RECRUITING

JILIN cancer hospital, Changchun

150081

NOT_YET_RECRUITING

Harbin Medical University cancer hospital, Harbin

200030

NOT_YET_RECRUITING

Shanghai Sixth People's Hospital, Shanghai

200120

NOT_YET_RECRUITING

Shanghai Jiaotong University School of Medicine, Tongji Hospital, Shanghai

210006

NOT_YET_RECRUITING

Nanjing First Hospital, Nanjing

230601

NOT_YET_RECRUITING

The Second Hospital Of Anhui Medical University, Hefei

250033

NOT_YET_RECRUITING

The Second Hospital of Shandong University, Jinan

250117

NOT_YET_RECRUITING

Shandong Cancer Hospital, Jinan

261000

NOT_YET_RECRUITING

Weifang people's Hospital, Weifang

300070

NOT_YET_RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

300202

RECRUITING

Tianjin Medical University Cancer Institute&Hospital, Tianjin

310005

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou

330006

NOT_YET_RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

330029

NOT_YET_RECRUITING

JIANGXI cancer hospital, Nanchang

350001

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

400038

NOT_YET_RECRUITING

The Southwest Hospital of Amu, Chongqing

410000

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

430000

NOT_YET_RECRUITING

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

510060

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

541001

NOT_YET_RECRUITING

Affiliated Hospital of Guilin Medical University, Gui'lin

545006

NOT_YET_RECRUITING

The Second Affiliated Hospital Of GXUST, Liuzhou

570102

NOT_YET_RECRUITING

The First Affiliated Hospital of Hainan Medical University, Hainan

610000

NOT_YET_RECRUITING

West China Hospital of Si chuan University, Chengdu

650118

NOT_YET_RECRUITING

Yunnan Cancer Hospital, Kunming

710000

NOT_YET_RECRUITING

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an

710032

NOT_YET_RECRUITING

Xijing Hospital, Xi'an

710068

NOT_YET_RECRUITING

Shaanxi Provincial People'S Hospital, Xi'an

730050

NOT_YET_RECRUITING

Gansu Provincial Cancer Hospital, Lanzhou

841100

NOT_YET_RECRUITING

Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY